Eli Lilly's biggest growth drivers today are its weight loss drugs.
These stocks might not be small for too much longer.
Could Amgen be the next stock to soar due to a GLP-1 drug?
The future keeps getting brighter for these companies.
Its latest medicines for obesity and type 2 diabetes are selling rapidly.
Both of these businesses are finding traction in a pair of major markets.
Eli Lilly just took a page out of Novo Nordisk's book.
These three companies have track records that should please investors.
Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects....
This mid-cap biopharma may one day be a titan of the industry.